Until now, no valid prognostic biomarkers for colon cancer chemotherapy have been established, although several potential molecular predictors of recurrence risk and chemotherapy benefit have been investigated (e.g., KRAS expression, levels of DNA mismatch repair, and p53 expression) [21, 22]. This evidence concerns the gene TP53 and malignant colon neoplasm.